抗体の世界市場:産業分析・機会分析

◆英語タイトル:Antibodies Market: Global Industry Analysis and Opportunity Assessment 2016 - 2026
◆商品コード:FMI609200
◆発行会社(調査会社):Future Market Insights
◆発行日:2016年7月15日
◆ページ数:198
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Individual (single user)USD3,500 ⇒換算¥399,000見積依頼/購入/質問フォーム
EnterpriseUSD7,000 ⇒換算¥798,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はFuture Market Insights社の日本における正規販売代理店です。Future Market Insights社の概要及び新刊レポートはこちらでご確認いただけます。



※本調査レポートでは、抗体の世界市場について調査・分析し、市場概観、抗体の世界市場規模、市場規模予測、地域別分析(アメリカ、ヨーロッパ、アジア等)、セグメント別市場分析、競争状況、抗体市場動向、関連企業分析などを含め、以下の構成でお届けいたします。
【レポートの概要】

Future market insights offers a 10-year forecast on the global market for antibodies between 2016 and 2026. The global antibodies market is expected to witness a robust CAGR of 12.5% over the forecast period. The study demonstrates market dynamics that are expected to influence the current environment and future status of the global antibodies market over the forecast period. The primary objective of this report is to offer updates on trends, drivers, restraints, value forecasts, and opportunities for manufacturers operating in the global antibodies market.
Global demand for antibodies is increasing with growing burden of chronic illnesses such as cancer, autoimmune disorders and others. Developed markets such as the U.S. and Europe are witnessing increasing demand for antibody-based drugs due to rising demand for better treatment options. To understand and analyse the market, the report is categorically split into four sections, viz. market analysis by drug type, end user, indication, and regions. The report analyses the global antibodies market in terms of value (US$ Mn).

The global antibodies market is segmented on the basis of

Drug type
End User
Disease Indication
Region

The report begins with the market definition and defining different product types. This is followed by the overview on evolution of antibody based drugs. The market dynamics section includes FMI’s analysis on key trends, drivers, restraints, opportunities and macro factors influencing global antibodies market. Impact analysis of key growth drivers and restraints based on weighted average model has also been included in the report to better equip clients with crystal clear decision making insights.

The next section of the report analyses the market based on drug type and presents the forecast in terms of value for the next 10 years. Drug types covered in the report include:

Monoclonal antibodies
Polyclonal antibodies
Antibody drug conjugates

Monoclonal antibodies drug type segment holds highest market share in global antibodies market owing to high potential of these drugs for use in targeted therapies. Antibody-drug conjugates drug-type segment is expected to grow at significant CAGR over the forecast period due to unique property of exerting combined therapeutic effect of antibody and conjugated drug.

The next section of the report analyses market based on end user and presents the forecast in terms of value for the next ten years. The end users covered in this report are:

Hospitals
Long-term care facilities
Research institutes

The next section of the report analyses the market based on indications and presents the forecast in terms of value for the next ten years. The indications covered in the report include:

CNS Disorders
Cardiovascular Diseases
Cancer
Autoimmune disorders

Furthermore, the report analyses the market based on regions and presents the forecast in terms of value for the next ten years. Regions covered in the report include:

North America
U.S.
Canada
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Western Europe
UK
Germany
France
Spain
Italy
Nordic
Benelux
Rest of Western Europe
Eastern Europe
Russia
Poland
Rest of Eastern Europe
Asia Pacific Excluding Japan
China
India
ASEAN
Australia & New Zealand
Rest of APEJ
Middle East & Africa (MEA
GCC Countries
South Africa
North Africa
Rest of MEA
Japan

In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global antibodies market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective of the antibodies market. To understand key growth segments, Future Market Insights provides the ‘Attractiveness Index’ analysis. The resulting index helps providers to identify real market opportunities.

In the final section of the report on antibodies market, the ‘Competitive Landscape’ is included to provide report audiences with a dashboard view, to access the key differentiators among the competitor firms. Key categories of providers covered in the report are drug types. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the urinary tract infection value chain and the potential players with regard to the same. However, this section also includes market strategies and SWOT analysis of the main players in the market.

Detailed profiles of the medical device companies are also included in the scope of the report to evaluate their long-term and short-term strategies. Key players in the market include Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Eli Lilly and Co.

【レポートの目次】

Table Of Content

1. Executive Summary

2. Assumptions and Acronyms

3. Research Methodology

4. Antibodies Market Overview

4.1. Introduction

4.1.1. Antibodies Market Definition

4.1.2. Antibodies Market Taxonomy

4.1.3. Antibodies Market Product Type Overview

4.1.4. Overview

4.2. Antibodies Market Dynamics

4.2.1. Drivers

4.2.2. Restraints

4.2.3. Opportunity

4.3. Regulations

5. Global Antibodies Market Forecast

5.1. Market Value (US$ Mn) Forecast

5.1.1. Y-o-Y Growth Projections

5.1.2. Absolute $ Opportunity

5.2. Antibodies Market Trends

5.2.1. Market Share, By Region

5.2.2. Market Share, By Product Type

5.2.3. Market Share, By End User

5.2.4. Market Share, By Disease Indication

6. Global Antibodies Market Analysis, By Product Type

6.1. Introduction

6.1.1. Y-o-Y Growth Comparison, By Product Type

6.1.2. Market Share & Basis Point (BPS) Analysis, By Product Type

6.2. Market Forecast, By Product Type

6.2.1. Monoclonal antibodies

6.2.1.1. Absolute $ Opportunity

6.2.1.2. Market Value (US$ Mn) Forecast

6.2.2. Polyclonal antibodies

6.2.2.1. Absolute $ Opportunity

6.2.2.2. Market Value (US$ Mn) Forecast

6.2.3. Antibody-drug complexes (ADCs)

6.2.3.1. Absolute $ Opportunity

6.2.3.2. Market Value (US$ Mn) Forecast

6.3. Market Attractiveness Analysis, By Product Type

6.4. Prominent Trends

7. Global Antibodies Market Analysis, By Disease Indication

7.1. Introduction

7.1.1. Y-o-Y Growth Comparison, By Disease Indication

7.1.2. Market Share & Basis Point (BPS) Analysis, By Disease Indication

7.2. Market Forecast, By Disease Indication

7.2.1. Cardiovascular diseases

7.2.1.1. Absolute $ Opportunity

7.2.1.2. Market Value (US$ Mn) Forecast

7.2.2. CNS disorders

7.2.2.1. Absolute $ Opportunity

7.2.2.2. Market Value (US$ Mn) Forecast

7.2.3. Cancer

7.2.3.1. Absolute $ Opportunity

7.2.3.2. Market Value (US$ Mn) Forecast

7.2.4. Autoimmune Disorders

7.2.4.1. Absolute $ Opportunity

7.2.4.2. Market Value (US$ Mn) Forecast

7.3. Market Attractiveness Analysis, By Disease Indication

7.4. Prominent Trends

8. Global Antibodies Market Analysis, By End User

8.1. Introduction

8.1.1. Y-o-Y Growth Comparison, By End User

8.1.2. Market Share & Basis Point (BPS) Analysis, By End User

8.2. Market Forecast, By End User

8.2.1. Hospitals

8.2.1.1. Absolute $ Opportunity

8.2.1.2. Market Value (US$ Mn) Forecast

8.2.2. Long-term Care Facilities

8.2.2.1. Absolute $ Opportunity

8.2.2.2. Market Value (US$ Mn) Forecast

8.2.3. Research institutes

8.2.3.1. Absolute $ Opportunity

8.2.3.2. Market Value (US$ Mn) Forecast

8.3. Market Attractiveness Analysis, By End User

8.4. Prominent Trends

9. Global Antibodies Market Analysis, By Region

9.1. Introduction

9.1.1. Y-o-Y Growth Projections, By Region

9.1.2. Market Share & Basis Point (BPS) Analysis, By Region

9.2. Market Forecast, By Region

9.2.1. North America Market Value (US$ Mn) Forecast

9.2.2. Latin America Market Value (US$ Mn) Forecast

9.2.3. Western Europe Market Value (US$ Mn) Forecast

9.2.4. Eastern Europe Market Value (US$ Mn) Forecast

9.2.5. Asia Pacific Excl. Japan Market Value (US$ Mn) Forecast

9.2.6. Japan Market Value (US$ Mn) Forecast

9.2.7. MEA Market Value (US$ Mn) Forecast

9.3. Regional Attractiveness Analysis

10. North America Antibodies Market Analysis

10.1. Introduction

10.1.1. Y-o-Y Growth Projections, By Country

10.1.2. Market Share & Basis Point (BPS) Analysis, By Country

10.2. Key Regulations

10.3. Key Trends

10.4. North America Market Forecast

10.4.1. Market Value (US$ Mn) Forecast, By Country

10.4.1.1. U.S. Absolute $ Opportunity

10.4.1.2. Canada Absolute $ Opportunity

10.4.2. Market Value (US$ Mn) Forecast, By Product Type

10.4.2.1. Monoclonal antibodies

10.4.2.2. Polyclonal antibodies

10.4.2.3. Antibody-drug complexes (ADCs)

10.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

10.4.3.1. Cardiovascular diseases

10.4.3.2. CNS disorders

10.4.3.3. Cancer

10.4.3.4. Autoimmune Disorders

10.4.4. Market Value (US$ Mn) Forecast, By End User

10.4.4.1. Hospitals

10.4.4.2. Long-term Care Facilities

10.4.4.3. Research institutes

10.5. Market Attractiveness Analysis

10.5.1. By Country

10.5.2. By Product Type

10.5.3. By End User

10.5.4. By Disease Indication

10.6. Drivers & Restraints: Impact Analysis

11. Latin America Antibodies Market Analysis

11.1. Introduction

11.1.1. Y-o-Y Growth Projections, By Country

11.1.2. Market Share & Basis Point (BPS) Analysis, By Country

11.2. Key Regulations

11.3. Key Trends

11.4. Latin America Market Forecast

11.4.1. Market Value (US$ Mn) Forecast, By Country

11.4.1.1. Argentina Absolute $ Opportunity

11.4.1.2. Brazil Absolute $ Opportunity

11.4.1.3. Mexico Absolute $ Opportunity

11.4.1.4. Rest of Latin America Absolute $ Opportunity

11.4.2. Market Value (US$ Mn) Forecast, By Product Type

11.4.2.1. Monoclonal antibodies

11.4.2.2. Polyclonal antibodies

11.4.2.3. Antibody-drug complexes (ADCs)

11.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

11.4.3.1. Cardiovascular diseases

11.4.3.2. CNS disorders

11.4.3.3. Cancer

11.4.3.4. Autoimmune Disorders

11.4.4. Market Value (US$ Mn) Forecast, By End User

11.4.4.1. Hospitals

11.4.4.2. Long-term Care Facilities

11.4.4.3. Research institutes

11.5. Market Attractiveness Analysis

11.5.1. By Country

11.5.2. By Product Type

11.5.3. By End User

11.5.4. By Disease Indication

11.6. Drivers & Restraints: Impact Analysis

12. Western Europe Antibodies Market Analysis

12.1. Introduction

12.1.1. Y-o-Y Growth Projections, By Country

12.1.2. Market Share & Basis Point (BPS) Analysis, By Country

12.2. Key Regulations

12.3. Key Trends

12.4. Western Europe Market Forecast

12.4.1. Market Value (US$ Mn) Forecast, By Country

12.4.1.1. U.K. Absolute $ Opportunity

12.4.1.2. Germany Absolute $ Opportunity

12.4.1.3. France Absolute $ Opportunity

12.4.1.4. Spain Absolute $ Opportunity

12.4.1.5. Italy Absolute $ Opportunity

12.4.1.6. Nordic Countries Absolute $ Opportunity

12.4.1.7. Rest of Western Europe Absolute $ Opportunity

12.4.2. Market Value (US$ Mn) Forecast, By Product Type

12.4.2.1. Monoclonal antibodies

12.4.2.2. Polyclonal antibodies

12.4.2.3. Antibody-drug complexes (ADCs)

12.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

12.4.3.1. Cardiovascular diseases

12.4.3.2. CNS disorders

12.4.3.3. Cancer

12.4.3.4. Autoimmune Disorders

12.4.4. Market Value (US$ Mn) Forecast, By End User

12.4.4.1. Hospitals

12.4.4.2. Long-term Care Facilities

12.4.4.3. Research institutes

12.5. Market Attractiveness Analysis

12.5.1. By Country

12.5.2. By Product Type

12.5.3. By End User

12.5.4. By Disease Indication

12.6. Drivers & Restraints: Impact Analysis

13. Eastern Europe Antibodies Market Analysis

13.1. Introduction

13.1.1. Y-o-Y Growth Projections, By Country

13.1.2. Market Share & Basis Point (BPS) Analysis, By Country

13.2. Key Regulations

13.3. Key Trends

13.4. Eastern Europe Market Forecast

13.4.1. Market Value (US$ Mn) Forecast, By Country

12.4.1.1. Poland Absolute $ Opportunity

12.4.1.2. Russia Absolute $ Opportunity

12.4.1.3. Rest of Eastern Europe Absolute $ Opportunity

13.4.2. Market Value (US$ Mn) Forecast, By Product Type

13.4.2.1. Monoclonal antibodies

13.4.2.2. Polyclonal antibodies

13.4.2.3. Antibody-drug complexes (ADCs)

13.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

13.4.3.1. Cardiovascular diseases

13.4.3.2. CNS disorders

13.4.3.3. Cancer

13.4.3.4. Autoimmune Disorders

13.4.4. Market Value (US$ Mn) Forecast, By End User

13.4.4.1. Hospitals

13.4.4.2. Long-term Care Facilities

13.4.4.3. Research institutes

13.5. Market Attractiveness Analysis

13.5.1. By Country

13.5.2. By Product Type

13.5.3. By End User

13.5.4. By Disease Indication

13.6. Drivers & Restraints: Impact Analysis

14. Asia Pacific Excl. Japan Antibodies Market Analysis

14.1. Introduction

14.1.1. Y-o-Y Growth Projections, By Country

14.1.2. Market Share & Basis Point (BPS) Analysis, By Country

14.2. Key Regulations

14.3. Key Trends

14.4. Asia Pacific Excl. Japan Market Forecast

14.4.1. Market Value (US$ Mn) Forecast, By Country

14.4.1.1. China Absolute $ Opportunity

14.4.1.2. India Absolute $ Opportunity

14.4.1.3. ASEAN Absolute $ Opportunity

14.4.1.4. Australia & New Zealand Absolute $ Opportunity

14.4.1.5. Rest of APEJ Absolute $ Opportunity

14.4.2. Market Value (US$ Mn) Forecast, By Product Type

14.4.2.1. Monoclonal antibodies

14.4.2.2. Polyclonal antibodies

14.4.2.3. Antibody-drug complexes (ADCs)

14.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

14.4.3.1. Cardiovascular diseases

14.4.3.2. CNS disorders

14.4.3.3. Cancer

14.4.3.4. Autoimmune Disorders

14.4.4. Market Value (US$ Mn) Forecast, By End User

14.4.4.1. Hospitals

14.4.4.2. Long-term Care Facilities

14.4.4.3. Research institutes

14.5. Market Attractiveness Analysis

14.5.1. By Country

14.5.2. By Product Type

14.5.3. By End User

14.5.4. By Disease Indication

14.6. Drivers & Restraints: Impact Analysis

15. Japan Antibodies Market Analysis

15.1. Introduction

15.2. Key Regulations

15.3. Key Trends

15.4. Japan Market Forecast

15.4.1. Market Value (US$ Mn) Forecast, By Product Type

15.4.1.1. Monoclonal antibodies

15.4.1.2. Polyclonal antibodies

15.4.1.3. Antibody-drug complexes (ADCs)

15.4.2. Market Value (US$ Mn) Forecast, By Disease Indication

15.4.2.1. Cardiovascular diseases

15.4.2.2. CNS disorders

15.4.2.3. Cancer

15.4.2.4. Autoimmune Disorders

15.4.3. Market Value (US$ Mn) Forecast, By End User

15.4.3.1. Hospitals

15.4.3.2. Long-term Care Facilities

15.4.3.3. Research institutes

15.5. Market Attractiveness Analysis

15.5.1. By Product Type

15.5.2. By End User

15.5.3. By Disease Indication

15.6. Drivers & Restraints: Impact Analysis

16. MEA Antibodies Market Analysis

16.1. Introduction

16.1.1. Y-o-Y Growth Projections, By Country

16.1.2. Market Share & Basis Point (BPS) Analysis, By Country

16.2. Key Regulations

16.3. Key Trends

16.4. MEA Market Forecast

16.4.1. Market Value (US$ Mn) Forecast, By Country

16.4.1.1. GCC Countries Absolute $ Opportunity

16.4.1.2. South Africa Absolute $ Opportunity

16.4.1.3. North Africa Absolute $ Opportunity

16.4.1.4. Rest of MEA Absolute $ Opportunity

16.4.2. Market Value (US$ Mn) Forecast, By Product Type

16.4.2.1. Monoclonal antibodies

16.4.2.2. Polyclonal antibodies

16.4.2.3. Antibody-drug complexes (ADCs)

16.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

16.4.3.1. Cardiovascular diseases

16.4.3.2. CNS disorders

16.4.3.3. Cancer

16.4.3.4. Autoimmune Disorders

16.4.4. Market Value (US$ Mn) Forecast, By End User

16.4.4.1. Hospitals

16.4.4.2. Long-term Care Facilities

16.4.4.3. Research institutes

16.5. Market Attractiveness Analysis

16.5.1. By Country

16.5.2. By Product Type

16.5.3. By End User

16.5.4. By Disease Indication

16.6. Drivers & Restraints: Impact Analysis

17. Competition Landscape

17.1. Company Share Analysis

17.2. Competition Dashboard

17.3. Company Profiles Inclusions

17.3.1. Revenue

17.3.2. Products/Brand Offerings

17.3.3. Key developments

17.3.4. SWOT Analysis

17.4. Company Profiled

17.4.1. Novartis AG

17.4.2. F. Hoffmann-La Roche Ltd.

17.4.3. Johnson & Johnson Services, Inc.

17.4.4. Takeda Pharmaceutical Company Limited

17.4.5. Amgen Inc.

17.4.6. Biogen Inc.

17.4.7. Bristol-Myers Squibb Company

17.4.8. AbbVie Inc.

17.4.9. Sanofi

17.4.10. Eli Lilly and Co.



【レポートのキーワード】

抗体

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[抗体の世界市場:産業分析・機会分析]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月06日現在 219,162 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆